Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dolmix
- Development stage
- Phase 3
- Lead developer
- Laboratórios Azevedos
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dolmix is an oral food supplement developed by Laboratórios Azevedos, formulated as tablets containing a combination of glucosamine sulphate (750 mg) and chondroitin sulphate (600 mg). It is indicated for joint health and mobility, particularly to support cartilage maintenance and alleviate symptoms associated with joint degeneration or nutrient deficiency. Glucosamine serves as a precursor for glycosaminoglycan biosynthesis, supporting cartilage structure, while chondroitin sulphate is a key component of the extracellular matrix and synovial fluid that helps maintain joint hydration and elasticity.
- Brand names
- Dolmix
- Other names
- Glucosamine sulfate + chondroitin sulfateGlucosamine Sulphate + Chondroitin Sulphate
Beyond the preview
Go deeper on Dolmix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dolmix.